DCI - Maysville is a medicare approved dialysis facility center in Maysville, Kentucky and it has 13 dialysis stations. It is located in Mason county at 1210 Pope Drive, Maysville, KY, 41056. You can reach out to the office of DCI - Maysville at (606) 759-7689. This dialysis clinic is managed and/or owned by Dialysis Clinic, Inc.. DCI - Maysville has the following ownership type - Non-Profit. It was first certified by medicare in November, 1997. The medicare id for this facility is 182541 and it accepts patients under medicare ESRD program.
| Name | DCI - Maysville |
|---|---|
| Location | 1210 Pope Drive, Maysville, Kentucky |
| No. of Dialysis Stations | 13 |
| Medicare ID | 182541 |
| Managed By | Dialysis Clinic, Inc. |
| Ownership Type | Non-Profit |
| Late Shifts | Yes |
| 1210 Pope Drive, Maysville, Kentucky, 41056 | |
| (606) 759-7689 | |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
| NPI Number | 1689607061 |
| Doing Business As | Dialysis Clinic Inc. |
| Address | 1210 Pope Dr Maysville, Kentucky, 41056 |
| Phone Number | (606) 759-7689 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 19 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 5 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 36 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 324 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 6 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 48 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at DCI - Maysville with elevated calcium levels.
| Patients with hypercalcemia | 42 |
| Hypercalcemia patient months | 385 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 44 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 18 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 23 |
| Patient months included in arterial venous fistula and catheter summaries | 218 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 58 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 32 |
| Hospitalization Rate in facility | 141.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 288.2 |
| Hospitalization Rate: Lower Confidence Limit | 73.6 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at DCI - Maysville were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 23.1 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 36.5 |
| Readmission Rate: Lower Confidence Limit | 12.3 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at DCI - Maysville get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 2.79 (Worse than Expected) |
| SIR: Upper Confidence Limit | 5.81 |
| SIR: Lower Confidence Limit | 1.13 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether DCI - Maysville's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 25 |
| Transfusion Rate in facility | 37.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 142.5 |
| Transfusion Rate: Lower Confidence Limit | 11.6 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at DCI - Maysville lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 167 |
| Mortality Rate in facility | 11.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 17.5 |
| Mortality Rate: Lower Confidence Limit | 7.2 |
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago
News Archive
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
An in-depth, authoritative assessment of women in university research has found that although there has been significant progress in the representation of women in the university research ranks, there are still gender equity challenges that must be overcome and the passage of time will not be enough to ensure parity.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
Increasing the flexibility and diagnostic capabilities in bi-plane vascular X-ray imaging, Toshiba America Medical Systems, Inc. introduces the all new Infinix™ VF-i/BP with large and mid-sized flat panel detectors. The large and mid-sized flat panel detectors provide clinicians with the ability to obtain critical variations in angle combinations while providing the necessary anatomical coverage, creating the optimal universal bi-plane vascular X-ray system for any clinical application.
A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.
› Verified 9 days ago